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Abstract
Background: Increased health care costs have made it incumbent on health-care facilities and physicians to
demonstrate both clinical and cost efficacy when recommending treatments. Though studies have examined the
cost-effectiveness of adjuvant goserelin with radiotherapy for locally advanced prostate cancer, few have compared
the cost-effectiveness of adjuvant goserelin to adjuvant chemotherapy alone in premenopausal breast cancer.
Methods: In this retrospective study at one hospital, the records of 152 patients with stage Ia to IIIa ER + breast
cancer who received goserelin or chemotherapy were reviewed. Survival analysis was assessed by the Kaplan-Meier
method. Patients were interviewed to evaluate their quality of life using the European Organization for Research
and Treatment Quality of Life questionnaire (EORTC-QLQ-C30, version 4.0), and to obtain the utility value by the
standard gamble (SG) and visual scale (VS) methods. Total medical cost was assessed from the (National Health
Insurance) NHI payer’s perspective.
Results: Survival at 11 years was significantly better in the groserelin group (P < 0.0012). The lifetime lost was
lower in the goserelin group (42 months vs. 66 months). The quality adjusted survival (QAS) of patients who
received goserelin was longer (122.5 ± 6.3 vs. 112.2 ± 6.7 months). Total expenses of goserelin were more than
cyclophosphamide, methotrexate, 5-fluorouracil (CMF) or 5-fluorouracil, epirubicin, cyclophosphamide (FEC)
chemotherapy regimes, but less than docetaxel, epirubicin (TE) or docetaxel, epirubicin, cyclophosphamide (TEC)
regimes. The quality-adjusted life-year was higher in the goserelin group.
Conclusions: Goserelin therapy results in better survival and higher utility-weighted life-years, and is more cost-
effective than TC or TEC chemotherapy.
Keywords: Adjuvant chemotherapy, Adjuvant hormone therapy, Goserelin, Estrogen-responsive (ER+), EORTC-QLQ-
C30, QALY, Breast cancer
Background
Endocrine therapy for premenopausal patients with pri-
mary breast cancer is based on reducing circulating
levels of estrogens. Because the ovary is a major contri-
butor of circulatory estrogen, therapies revolve around
reducing ovarian production. Chemotherapy decreases
estrogen levels due to cytotoxic effects on the ovaries.
Other available therapies to reduce estrogen levels
include ovarian ablation by either surgical removal or
radiotherapy, and pharmacological anti-estrogen therapy,
primarily with tamoxifen. Nevertheless, for premenopau-
sal women with breast cancer, protection of ovarian
function is important in order to maintain quality of life
(QoL) and fertility.
Luteinizing hormone-releasing hormone (LHRH) ana-
logues provide an alternative therapy. LHRH analogues
decrease ovarian estradiol production indirectly by act-
ing on the hypothalamic-pituitary-ovarian axis and inhi-
biting the secretion of pituitary gonadotrophins [1].
Chronic and reversible suppression of gonadotropin
secretion leads to a loss of ovarian steroid production–
an optimal antitumor environment for estrogen-
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ER + breast cancer patients, additional endocrine thera-
pies are recommended in order to increase the effective-
ness of the primary treatment [2].
Goserelin (Zoladex
®; Astra-Zeneca Pharmaceuticals
LP, Wilmington, DE, UK) is a widely-used LHRH analo-
gue shown to be effective and well-tolerated in patients
with advanced breast cancer, and has recently been the
focus of an international study that investigated its
effects on amenorrhea, hot flashes, and QoL as com-
pared to chemotherapy, or chemotherapy followed by
goserelin [3]. Since it has been observed to protect ovar-
ian function from damage by chemotherapy, it is also
used to decrease gonado-toxicity and prevent premature
menopause induced by chemotherapy in young, early
breast cancer patients when administered before and
during treatment [4,5]. Goserelin is associated with
fewer adverse events and comparative long-term dis-
ease-free survival and quality of life in patients with ER
+ breast cancer compared to chemotherapy alone
[3,6-8].
Quality of life is usually measured with a utility scale
or a health profile, and then summarized numerically.
From this, the expected quality-adjusted survival (QAS)
time can be calculated, which takes into account each of
the patient’s various health states and the survival dura-
tion (in years) spent in each state. The quality-adjusted
life-year (QALY) is also used for outcome evaluation, i.
e., for comparing the overall impact from both mortality
and morbidity of different health-related events [9,10].
In this study, both the QAS and QALY of patients who
received goserelin were estimated.
Another method for constructing a health profile for
long-term cancer survivors is to use survival-weighted
psychometric scores (SWPS) as an endpoint to compare
the efficacy of cancer treatments. The SWPS calculation
may also be extrapolated beyond the follow-up limit of
the patient cohort to obtain a life-long estimation of
QoL changes [11]. A semiparametric method can be
used to estimate life expectancy (LE), and foretell the
expected years of life lost (EYLL). The calculations can
be applied to clinical trials and can also be merged with
data pertaining to QoL, resulting in a more detailed out-
come assessment, effective optimization of cancer man-
agement, best use of different treatment protocols, and
most efficient resource allocation [12]. Because hormone
suppression treatment with goserelin is reversible at the
end of therapy, unlike oophorectomy and ablation, it is
an ideal candidate for a detailed study that integrates
QoL measurements.
Increased health care costs have made it incumbent
on health-care facilities and physicians to demonstrate
both clinical and cost efficacy when recommending
treatments. Though studies have examined the cost-
effectiveness of adjuvant goserelin with radiotherapy for
locally advanced prostate cancer [13,14], few have com-
pared the cost-effectiveness of adjuvant goserelin to
adjuvant chemotherapy alone in premenopausal breast
cancer patients. The present study evaluated the cost-
effectiveness of adjuvant goserelin or adjuvant che-
motherapy in stage Ia to IIIa ER + breast cancer patients
using health related quality of life (HRQoL) data. Costs
were estimated from the perspective of the National
Health Insurance (NHI; a mandatory health insurance
employed in Taiwan) payer.
Methods
Study design
Medical history and chart data of patients admitted to
the Department of General Surgery, Shin Kong Wu Ho-
Sun Memorial Hospital, from 1993 to 2007 were
reviewed. Eligible patients fulfilled the following criteria:
1) diagnosed with breast cancer before menopause; 2)
clinical staging between Ia and IIIa; 3) adjuvant che-
motherapy (at least 6 cycles) or goserelin therapy.
Patients who received tamoxifen were excluded from
the analysis.
Patients either underwent goserelin therapy (3.6 mg sub-
cutaneous depot injection into the abdominal wall every 4
weeks) or adjuvant chemotherapy (6 cycles of combined
therapy of CMF [cyclophosphamide, methotrexate, 5-
fluorouracil], FEC [5-fluorouracil, epirubicin, cyclopho-
sphamide], TE [docetaxel, epirubicin], or TEC [docetaxel,
epirubicin, cyclophosphamide]). Chemotherapy was dosed
by square meter of body surface area (BSA); common BSA
measurements for women are between 1.5 m
2 and 1.8 m
2.
Mean survival curves were calculated for the 2 treatment
groups, and subsequently adjusted for QoL. Between
August 30
th,2 0 0 7a n dD e c e m b e r2 9
th, 2007 152 patients
with stage Ia to IIIa disease who received goserelin for at
least 1 year, or received at least 6 cycles of chemotherapy
as adjuvant therapy were interviewed to evaluate their
QoL using the European Organization for Research and
Treatment QoL questionnaire (EORTC-QLQ-C30, version
4.0), and to obtain the utility value by the standard gamble
(SG) and visual scale (VS) methods. All interviews were
performed by 1 of 2 trained interviewers, and lasted on
average for 60 min.
Total medical cost
Total medical costs (surgical intervention, drugs, and
other health care services) were assessed from a payer’s
perspective, and based on standard claims submitted to
the NHI. Additional charges for blood tests, artificial
vessel placement (for chemotherapy), and granulocyte
colony-stimulating factor (GCSF) hormone, were also
included. Costs were expressed in Taiwan New Dollars
(TWD) and US dollars (USD), where 1 USD = 32 TWD.
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EORTC-QLQ-C30 is a reliable and sensitive 30-item,
cancer-specific, self-administered structured question-
naire designed to assess the quality of life of cancer
patients participating in international clinical trials [15].
All scales and single-item measures range in score from
0 to 100, with a higher score representing a higher
response level, or healthier level of functioning. A high
score on the global health status scale represents a high
QoL, though a high score for a symptom scale/item
represents a high level of symptoms/problems. A multi-
attribute utility scoring formula, based on SG utilities
derived from the power conversion of VS scores, was
used to calculate a utility score that reflects a respon-
dent’s preferences for the assessment of his/her health
status [16]. The multi-attribute utility analysis allows an
assignment of values to an individual’s health without
having to employ costly valuation procedures.
Statistical methods
EORTC-QLQ-C30 data were scored using the EORTC-
QLQ-C30 scoring manual [17]. Reference data was
matched for each patient, according to age and gender
from the Life Table of Taiwan, 1994. Expected years of
life lost were calculated by reference life year survival to
subtract index life year survival [8]. An 11-year and 50-
year survival analysis was performed by the Kaplan-
Meier method. QAS was assessed by multiplying the
overall survival for each year (determined by the area
under the Kaplan-Meier curve) by the average EORTC-
QLQ-CL30 score. To assess whether incremental costs
of goserelin therapy or chemotherapy were justified
from the perspective value attributed to different out-
comes between the 2 treatment groups, the QALY was
calculated in terms of gain. QALYs gained were calcu-
lated by: ICER = (costgoserelin -c o s t chemotherapy)/(QALYgo-
serelin -QALYchemotherapy).
Survival times of up to 600 months (50 years) were cal-
culated because the life expectancy of breast cancer is
about 20 years, and some of the patients are relatively
young (e.g., 25-40 years), thus there are patients who may
survive more than 30 or 40 years [12]. Therefore, in order
to accurately estimate the lifetime survival function, we
extrapolated to 50 years. The method has been mathema-
tically proven to be valid if the assumption of constant
excess hazard holds [18]. In fact, such an assumption gen-
erally holds for most cancers causing premature mortality,
namely, patients with breast cancer who survive generally
share the same likelihood of dying of other common
causes (acute myocardial infarction, stroke, traffic injuries,
etc.) in addition to their breast cancer after the first 1-2
years of life. Otherwise, the survival ratio of breast cancer
to age-, gender-matched referents would become stable
after the first 1-2 years of diagnosis.
Data were analyzed using SAS 9.0 (SAS Institute Inc.,




A total of 564 patient charts were reviewed. Patients
who underwent goserelin therapy presented with a
younger mean age (40.8 ± 6.5 years), shorter follow-up
duration (168 months vs. 273 months), and a higher 10-
year survival rate (Table 1).
From July 2007 to December 2007, 152 patients with
stage Ia to IIIa disease who received goserelin for at
least 1 year or received at least 6 cycles of chemotherapy
as adjuvant therapy were interviewed to obtain the uti-
lity value by the SG and VS methods. The 11-year survi-
val rate, described in Figure 1, indicates that patients
who received goserelin had a significantly better survival
rate than chemotherapy patients (P < 0.002). Figure 2,
which presents the extrapolated 50-year survival rates,
also reveals consistent findings.
QoL and utility values
Results of the EORTC-QLQ-C30 questionnaire revealed
that patients who received goserelin therapy had a
higher SG utility score than those who received che-
motherapy (0.81 ± 0.17 vs. 0.78 ± 0.23) (Table 2).
Patients who received goserelin therapy also displayed a
lesser amount of life-time lost (42 months vs. 66
months), and a longer life expectancy (432 ± 23 vs. 401
± 17 months). A comparatively lower QAS (341 ± 31 vs.
336 ± 39) was observed for goserelin patients (Table 3).
Quality-adjusted survival (QAS) of adjuvant goserelin
and adjuvant chemotherapy is shown in Figure 3. The
QALE of patients who received goserelin at an early
stage (122.5 ± 6.3 months) was longer than patients
who received chemotherapy at an early stage (112.2 ±
6.7 months). Figure 4 presents the QAS of adjuvant
goserelin and adjuvant chemotherapy for patients extra-
polated to 50 years. The QALE of patients who received
goserelin at an early stage (340.9 ± 30.6 months) was
Table 1 Patient demographic data
Adjuvant therapy
Goserelin Chemotherapy
Age (year) 40.8 ± 6.5 41.9 ± 5.7
Follow-up (month) 168 273
10-year survival rate 0.88 0.82
Life expectancy of patient population
(months)
432 ± 23 401 ± 17
Life expectancy of reference population
(months)
474 ± 1 467 ± 1
Life time lost (months) 42 66
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an early stage (335.7 ± 39.2 months).
Cost analysis
The total costs for 2 years of goserelin therapy and 6
cycles of chemotherapy from the perspective of the NHI
payer are presented in Table 4. Based on a BSA of 1.5
m
2, the total cost of goserelin (USD 5,532) was greater
than that of CMF (USD 1,789) and FEC (USD 3,604),
but less expensive than TE (USD 12,453) and TEC
(USD 12,517). A similar result was found when the
costs were calculated based on a BAS of 1.8 m
2.T h e
QALY was higher in the goserelin group as compared
to chemotherapy groups by either SG or VS. Goserelin
versus CMF had the highest ICERs among the 4
chemotherapeutic drug regimes. The ICERs were: 1,891
USD (BSA 1.5 m
2) or 1,887 USD (BSA 1.8 m
2)b yS G ,
and 2,283 USD (BSA 1.5 m
2) or 2,279 USD (BSA 1.8
m
2) by VS. Goserelin versus TEC had the lowest ICERs:
-3,528 USD (BSA 1.5 m
2) or -4,200 USD (BSA 1.8 m
2)
by SG, and -4,259 USD (BSA 1.5 m




There are approximately 6,500 new cases of breast can-
cer diagnosed per year in Taiwanese women, and most
are younger in age and more likely to be premenopausal
than their Western counterparts [19]. A recent report
indicated that > 50% of the total breast cancer cases
annually in Taiwan and China are in premenopausal
Figure 1 Survival curves of adjuvant goserelin and adjuvant chemotherapy for premenopausal breast cancer patients.
Figure 2 Survival curves of adjuvant goserelin and adjuvant chemotherapy for premenopausal breast cancer patients with
extrapolation of 50 years.
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protection of ovarian function is crucial for women
undergoing breast cancer therapy.
LHRH analogues decrease ovarian estradiol produc-
tion indirectly by impinging on the hypothalamic-pitui-
tary-ovarian axis, and inhibiting secretion of pituitary
gonadotrophins [2]. Chemotherapy usually results in
gonado-toxicity and induces damage of ovarian function.
Goserelin has been observed to protect ovarian function;
therefore, it is unlikely to induce premature menopause
and osteoporosis in young women [1,5]. In a phase II
pilot study, the addition of goserelin to adjuvant therapy
of premenopausal patients with early breast cancer was
well tolerated and shown to protect ovarian function
[3]. In our study, 86% of patients who were treated with
goserelin resumed normal menses, and 1 patient had a
pregnancy that ended with a normal childbirth 5 years
after treatment.
The present study evaluated the cost-effectiveness of
adjuvant goserelin therapy versus adjuvant chemother-
apy in premenopausal breast cancer patients with stage
Ia to IIIa disease. To our knowledge, this is the first
study evaluating the integration of goserelin into adju-
vant hormonal therapy in premenopausal breast cancer.
An illuminating study exploring women’s treatment pre-
ferences found that when healthy, premenopausal
women were given the choice of adjuvant goserelin or
CMF chemotherapy upon hypothetically developing ER
+ breast cancer, an overwhelming number chose gosere-
lin over chemotherapy [20]. The primary reasons for
choosing goserelin were to avoid the general side effects
of chemotherapy, in particular hair loss, and a lesser dis-
ruption of the activities of normal life with goserelin as
compared to chemotherapy. Other factors such as ferti-
lity, length of treatment, and amount of travel required
to receive treatments were discussed in the study; how-
ever, no comments regarding the cost of treatment were
made.
The results of our study indicate that goserelin is par-
ticularly cost-effective compared to TE and TEC che-
motherapy regimens, and comparable to CMF and FEC.
The cost of 2-year goserelin therapy appears more
expensive ($5,273 USD) than both CMF (approximately
$1,666 USD) and FEC (approximately $1,872), regardless
of BSA, but higher QALY is seen. Based on the
EORTC-QLQ-CL30 scores from our study, patients who
receive goserelin therapy have higher QoL. Similarly,
there are positive ICERs for goserelin vs. CMF and FEC,
but negative ICERs for goserelin vs. TE and TEC.
There have been 4 large multi-center studies compar-
ing efficacy outcomes between adjuvant goserelin (3.6
mg depot) and adjuvant chemotherapy. These are the
German Adjuvant Breast Cancer Group (GABG) trial
IV-A-93 [21], the Austrian Breast and Colorectal Cancer
Study Group Trial 5 (ABCSG) [22], the International
Breast Cancer Study Group (IBCSG) Trial VIII [7], and
the Zoladex Early Breast Cancer Research Association
Trialists’ Group (ZEBRA) [6]. Of these, the IBCSG trial
VIII, ABCSG trial VI, and ZEBRA examined CMF for 6
cycles (28 days each), whereas the GABG trial IV-A-93
examined intravenous cyclophosphamide.
The ZEBRA study [6], the largest, consisted of primar-
ily ER + patients (1189/1614, 73.7%,) and demonstrated
comparable recurrence-free survival, overall survival,
and frequency of adverse effects at 6 years for ER +
patients, but not for ER- and ER-unknown status
patients, a trend seen in the other trials. The IBCSG
and ZEBRA trials also indicated significantly better QoL
during the first year in patients receiving goserelin, but
little difference thereafter [6,23]. The ABCSG trial con-
cluded that goserelin and tamoxifen were significantly
more effective, with increased local recurrence-free sur-
vival and relapse-free survival as compared to CMF pre-
menopausal women with stage I and II breast cancer
[22]. An update on the ZEBRA study at a median fol-
low-up of 7.3 years confirmed the previously reported
outcomes for overall survival, and demonstrated the
effectiveness of goserelin as an alternative to CMF for
adjuvant therapy of premenopausal ER + women with
early breast cancer [24].
Taken together, the results of the aforementioned
trials are consistent with the present finding that adju-
vant CMF and FEC produced comparative HRQoL uti-
lity values (0.81 vs. 0.78) at last follow-up, and appeared
more economically sound than goserelin, in premeno-
pausal patients with early stage breast cancer. It should
be noted, however, that although the cost of goserelin
may seem exorbitant relative to CMF and FEC, hormo-
nal therapy administered in the early stages of breast
Table 2 HRQoL utility values as per multi-attribute utility
analysis
Goserelin Chemotherapy
Age 42.6 ± 7.3 45.6 ± 6.5
Mean of SG 0.81 ± 0.17 0.78 ± 0.23
Table 3 Quality-adjusted survival (QAS) estimated from a
sample through the standard gamble (SG) method
Goserelin Chemotherapy
Life expectancy of patient population 432 ± 23 401 ± 17
Life expectancy of reference population 474 ± 1 467 ± 1
SG of patient population 0.81 0.78
SG of reference population 1 1
QAS of patient population 341 ± 31 336 ± 39
QAS of reference population 476 ± 1 468 ± 1
QAS lost 135 132
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outcomes of other common medical interventions.
While no cost-utility studies exist on adjuvant gosere-
lin therapy in breast cancer alone, analyses of CMF and
FEC have been extensively reported. Total costs of adju-
vant CMF therapy in breast cancer have been reported
to be approximately $3,852 USD-$10,197 USD (for 9
cycles) in Norway 1998-2000 [25], which amounts to
approximately $1,688 USD per life-year saved in the US
in the year 1992 [26], with drug costs accounting for
40% in both cases. CMF (for 6 cycles) in the present
study is the most affordable regimen (approximately
$1,788 USD for a BSA of 1.5 m
2 and $1,795 USD for a
BSA of 1.8 m
2), and differences in costs may likely
reflect differences in national costs, rather than any
major differences in treatment regimen.
Our review of prior economic evaluation research
related to breast cancer treatment revealed the first
cost-benefit analysis report discussing post-surgery adju-
vant therapy for breast cancer was published in the
early 1990s [27]. In the evaluation report comparing
tamoxifen, chemotherapy, and combination therapy,
Smith analyzed treatments that were suitable for differ-
ent disease symptoms in patients with breast cancer >
45 years old and before menopause. The authors con-
cluded that in premenopausal early-stage breast cancer,
chemotherapy adds substantial clinical benefit at a mod-
e s tc o s tw h i l et a m o x i f e na l o ne adds meaningful benefit
Figure 3 Quality-adjusted survival (QAS) of adjuvant goserelin and adjuvant chemotherapy for premenopausal breast cancer patients.
Figure 4 Quality-adjusted survival (QAS) of adjuvant goserelin and adjuvant chemotherapy for premenopausal breast cancer patients
with extrapolation of 50 years.
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tive for all women, but is most beneficial and only cost-
effective in ER + women.
Several reports evaluating the cost-benefit of che-
motherapy for breast cancer exist in the literature. One
report analyzing node positive breast cancer patients
and comparing the cost-benefit ratio with/without CMF
as adjuvant therapy revealed an ICER value of approxi-
mately $447 USD per person, per year [28]. Another
study comparing the cost-benefit of 2 combination
therapies, TAC (docetaxel, doxorubicin, and cyclopho-
sphamide) and FAC (fluorouracil, doxorubicin, and
cyclophosphamide), utilized a decision-making model
from the England National Health Service [29]. The
result showed that when using FAC as a standard, for
an increase of 1 unit of TAC per person, per year, the
corresponding cost was £15,418, while for an increase of
1 unit of QALY, the corresponding cost was £18,188.
The present study has a number of limitations. First,
using multi-attribute utility analysis may have resulted
in an overestimated VS before power conversion into an
SG score. Also, robustness of the utility analysis could
not be ascertained, as a sensitivity analysis was not per-
formed. Second, the results reflect the NHI system of
Taiwan. Thus, when estimating costs, total medical
costs (surgical intervention, drugs, and other health care
services) were assessed from a payer’s perspective, and
based on standard claims submitted to the NHI. How-
ever, the NHI has restrictions on the prescribing of
goserelin. Prescription of goserelin requires pre-registry,
and is limited to patients who are unsuitable for hyster-
ectomy, or fail to respond to other hormone therapy (e.
g., tamoxifen, megestrol). Therefore, goserelin is consid-
ered a second line therapeutic agent. Additionally, the
cost data that was utilized reflects the Taiwanese socie-
tal perspective. Thus, cost-utility thresholds employed in
other countries cannot be directly applied. Lastly,
because the data retrieved was from the time period of
1993 to 2007, there was a large amount of missing data
with respect to patient characteristics, thus we only pre-
sented the data set that was complete, age.
Conclusion
In conclusion, this study indicates that adjuvant gosere-
lin therapy in premenopausal women with breast cancer
is particularly cost-effective when compared to TE and
TEC adjuvant chemotherapy regimens, but more expen-
sive (at the cost of higher QALY gained) when
Table 4 The total costs (USD) in the adjuvant treatment of premenopausal patients with stage Ia to IIIa breast cancer
in Taiwan
Drug Costs Surgery G-CSF Treatment Blood Testing Chemo Costs Total Costs
BSA 1.5 m
2 BSA 1.8 m
2 BSA 1.5 m
2 BSA 1.8 m
2
Goserelin 5,532 0 0 0 0 5,532
Chemotherapy
CMF 149 156 438 651 59 492 1,789 1,795
FEC 1,964 1,970 438 651 59 492 3,603 3,610
TE 10,813 12,145 438 651 59 492 12,453 13,785
TEC 10,878 12,210 438 651 59 492 12,517 13,849
BSA, body surface area; CMF, (cyclophosphamide, methotrexate, 5-fluorouracil); FEC, (5-fluorouracil, epirubicin, cyclophosphamide); TE (docetaxel, epirubicin); TEC,
(docetaxel, epirubicin, cyclophosphamide)




SG VS BSA 1.5 m
2 BSA 1.8 m
2 SG VS
BSA 1.5 m
2 BSA 1.8 m
2 BSA 1.5 m
2 BSA 1.8 m
2
Goserelin 8.81 8.78 5,532
Chemotherapy
CMF 6.83 7.14 1,789 1,792 1,891 1,887 2,283 2,279
FEC 6.83 7.14 3,606 3,610 974 971 1,176 1,172
TE 6.83 7.14 12,453 13,785 -3,495 -4,168 -4,220 -5,032
TEC 6.83 7.14 12,517 13,849 -3,528 -4,200 -4,259 -5,071
aICER = (costgoserelin - cost chemothreapy )/(QALYgoserelin -Q A L Y chemothre)
BSA, body surface area; CMF, (cyclophosphamide, methotrexate, 5-fluorouracil); FEC, (5-fluorouracil, epirubicin, cyclophosphamide); TE (docetaxel, epirubicin); TEC,
(docetaxel, epirubicin, cyclophosphamide)
Cost in US dollars
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motherapy demonstrate comparable efficacy in terms of
HRQoL at final follow-up. Goserelin, however, leads to
a better QoL for younger breast cancer patients.
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